EVERIMEN Study (EVERIMEN Study)

Recruiting

• Conditions: androgenetic alopecia

• Registration Number: jRCTs051240303

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-26
• Last Update Posted: 2025-03-26

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

1. Patients diagnosed with androgenetic alopecia in males
2. Patients diagnosed with Hamilton-Norwood classification type II Vertex, III Vertex, IV, and V
3. Patients who have used minoxidil, 5-alpha reductase inhibitors, or both in the past (including ongoing use) but are dissatisfied with the results and wish to receive stem cell supernatant fluid
4. Patients aged 18 years or older
5. Patients who have given written informed consent

Exclusion Criteria

1. Patients undergoing treatment for malignant tumours
2. Patients with concurrent hair loss other than androgenetic alopecia
3. Patients who have previously undergone stem cell supernatant solution treatment for the scalp
4. Patients who have started or changed their treatment for androgenetic alopecia within 6 months prior to obtaining consent
5. Patients currently participating in another clinical trial
6. Patients deemed inappropriate as subjects by the principal investigator (subinvestigator)

Study & Design

• Study Type: Interventional
• Study Design: single assignment

Primary Outcome Measures

Name	Time	Method
-		Change in scalp hair density from baseline to 32 weeks of treatment (strands/cm2)

Secondary Outcome Measures

Name	Time	Method
Changes in scalp hair density		Changes in scalp hair density (strands/cm²)
Modified Global Photographic Assessment (MGPA) score	16, 32 and 52 weeks post-treatment	Modified Global Photographic Assessment (MGPA) score
Changes in Dermatology Life Quality Index (DLQI)		Changes in Dermatology Life Quality Index (DLQI)
Subject satisfaction with treatment	32 and 52 weeks	Subject satisfaction with treatment